<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2019-3-75-80</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-762</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РАЗНОЕ</subject></subj-group></article-categories><title-group><article-title>Прогнозирование риска развития больших кардиоваскулярных событий у больных хронической обструктивной болезнью легких в сочетании с дисфункцией почек</article-title><trans-title-group xml:lang="en"><trans-title>Predicting of the risk of major cardiovascular events developing in patients with chronic obstructive pulmonary disease in combination with renal dysfunction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6257-354X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Болотова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bolotova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктр медицинских наук профессор кафедры терапии № 1 ФПК и ППС</p><p>Краснодар</p></bio><bio xml:lang="en"/><email xlink:type="simple">bolotowa_e@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Являнская</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yavlyanskaya</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заочный аспирант кафедры терапии № 1 ФПК и ППС  ФГБОУ ВО “Кубанский государственный медицинский университет” Минздрава России, врач-эндокринолог, терапевт ГБУЗ “Краевая клиническая больница № 2” Минздрава Краснодарского края</p><p>Краснодар</p></bio><bio xml:lang="en"/><email xlink:type="simple">rahill_de_novo@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудникова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudnikova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, врач-терапевт, функциональный диагност</p><p>Краснодар</p></bio><bio xml:lang="en"/><email xlink:type="simple">avdudnikova@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО “Кубанский государственный медицинский университет” Минздрава России</institution></aff><aff xml:lang="en"><institution>Kuban State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО “Кубанский государственный медицинский университет” Минздрава России;&#13;
ГБУЗ “Краевая клиническая больница № 2” Минздрава Краснодарского края</institution></aff><aff xml:lang="en"><institution>Kuban State Medical University;&#13;
Regional Clinical Hospital № 2</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ “Краевая клиническая больница № 2” Минздрава Краснодарского края</institution></aff><aff xml:lang="en"><institution>Regional Clinical Hospital № 2</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>13</day><month>06</month><year>2019</year></pub-date><volume>18</volume><issue>3</issue><fpage>75</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Болотова Е.В., Являнская В.В., Дудникова А.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Болотова Е.В., Являнская В.В., Дудникова А.В.</copyright-holder><copyright-holder xml:lang="en">Bolotova E.V., Yavlyanskaya V.V., Dudnikova A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/762">https://cardiovascular.elpub.ru/jour/article/view/762</self-uri><abstract><sec><title>Цель</title><p>Цель. Определение независимых предикторов больших кардиоваскулярных событий (БКВС) у пациентов с хронической обструктивной болезнью легких (ХОБЛ) в сочетании с ранними стадиями хронической болезни почек (ХБП).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включены 279 пациентов с ХОБЛ 2-4 степени тяжести согласно классификации GOLD 2014г. На первом этапе у всех пациентов находили потенциальные факторы риска БКВС и определяли уровень витамина Д (25(ОН)Д. Через 12 мес. у всех пациентов собирали анамнез БКВС. Пациенты были разделены на 2 группы: имевшие БКВС в течение предшествующих 12 мес., и без них. Факторы риска развития БКВС, достоверно различающиеся между двумя группами по результатам унивариантного анализа далее последовательно включали в логистическую регрессию для определения достоверных независимых предикторов БКВС. Для определения переменных проводили ROC-анализ с целью выявления прогностической точки отсечения.</p></sec><sec><title>Результаты</title><p>Результаты. Группу пациентов, перенесших БВКС, составили 37 человек, у которых были зафиксированы 40 БКВС. Из регистрируемых показателей у больных ХОБЛ в сочетании с ранней стадией ХБП достоверно вносили вклад в развитие БКВС, уровень витамина Д, частота обострений за предшествующие 12 мес., скорость клубочковой фильтрации (СКФ), сумма баллов по шкале PROCAM. Для построенного уравнения регрессии коэффициент детерминации определен как R2=0,76, критерий Хосмера-Лемешова =0,8. Площадь под кривой для модели =0,95. По результатам ROC-анализа установлено, что независимыми предикторами развития БКВС в 12-месячный срок у пациентов с ХОБЛ в сочетании с ранними стадиями ХБП являются: сумма баллов по шкале PROCAM &gt;56, частота обострений ХОБЛ за предшествующие 12 мес. &gt;2, СКФ &lt;80 мл/мин/1,73 м2, уровень витамина Д &lt;34,3 нг/мл.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To identify the independent predictors of major cardiovascular events (MCVE) in patients with chronic obstructive pulmonary disease (COPD) in combination with the early stages of chronic kidney disease (CKD).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 279 patients with GOLD 2014 2-4 severity COPD. At the first stage, we surveyed the potential risk factors for MCVE and the level of 25-OH vitamin D. After 12 months, all patients had a history of MCVE. Patients were divided into 2 groups: those who had MCVE during the previous 12 months, and without them. The risk factors for the development of MCVE, significantly differing between the two groups according to the results of a univariate analysis, were included in the logistic regression to determine reliable independent predictors of MCVE. We also studied ROC curve to identify the prognostic cut-off point.</p></sec><sec><title>Results</title><p>Results. The group of patients who had MCVE consisted of 37 people with 40 MCVE cases. In patients with COPD in combination with the early stage of CKD, the level of vitamin D, the frequency of exacerbations in the preceding 12 months, the glomerular filtration rate (GFR), the score of PROCAM scale significantly influence to the development of MCVE. For the constructed regression equation, the determination coefficient is defined as R2=0,76, Hosmer-Lemeshov criterion =0,8. The area under the curve for the model =0,95. According to the results of the ROC analysis, it was found that independent predictors of MCVE in a 12-month period in patients with COPD and CKD (early stages) are: the sum of PROCAM scale points &gt;56, the frequency of COPD exacerbations for the previous 12 months &gt;2, GFR &lt;80 ml/min/1,73 m2, the level of vitamin D &lt;34,3 ng/ml.</p></sec><sec><title>Conclusion</title><p>Conclusion. Independent predictors of MCVE in a 12-month period in patients with COPD and the early stages of CKD are: the score of the PROCAM scale &gt;56, the frequency of exacerbations of COPD in the preceding 12 months &gt;2, GFR &lt;80 ml/min/1,73 m2, the level of vitamin D &lt;34,3 ng/ml.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>витамин Д</kwd><kwd>кардиоваскулярный риск</kwd></kwd-group><kwd-group xml:lang="en"><kwd>vitamin D</kwd><kwd>cardiovascular risk</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Report GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org. January 2015.</mixed-citation><mixed-citation xml:lang="en">Report GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org  January 2015.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706. doi:10.1016/S2213-2600(17)30293-X.</mixed-citation><mixed-citation xml:lang="en">Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706. doi:10.1016/S2213-2600(17)30293-X.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshizawa T, Okada K, Furuichi S, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int J Chron Obstruct Pulmon Dis. 2015;10:1283-9. doi:10.2147/COPD.S80673.</mixed-citation><mixed-citation xml:lang="en">Yoshizawa T, Okada K, Furuichi S, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int J Chron Obstruct Pulmon Dis. 2015;10:1283-9. doi:10.2147/COPD.S80673.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013;84(3):622-3. doi:10.1038/kisup.2012.37.</mixed-citation><mixed-citation xml:lang="en">KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013;84(3):622-3. doi:10.1038/kisup.2012.37.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091-7. doi:10.1378/chest.09-2029.</mixed-citation><mixed-citation xml:lang="en">Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091-7. doi:10.1378/chest.09-2029.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Halpin DM, Decramer M, Celli B, et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT Trial. Lung. 2011;189:261- 8. doi:10.1007/s00408-011-9301-8.</mixed-citation><mixed-citation xml:lang="en">Halpin DM, Decramer M, Celli B, et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT Trial. Lung. 2011;189:2618. doi:10.1007/s00408-011-9301-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Portegies ML, Lahousse L, Joos GF, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. Am J Respir Crit Care Med. 2016;193(3):251-8. doi:10.1164/rccm.201505-0962OC.</mixed-citation><mixed-citation xml:lang="en">Portegies ML, Lahousse L, Joos GF, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. Am J Respir Crit Care Med. 2016;193(3):251-8. doi:10.1164/rccm.201505-0962OC.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Windsor C, Herrett E, Smeeth L, et al. No association between exacerbation frequency and stroke in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:217-25. doi:10.2147/COPD.S95775.</mixed-citation><mixed-citation xml:lang="en">Windsor C, Herrett E, Smeeth L, et al. No association between exacerbation frequency and stroke in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:217-25. doi:10.2147/COPD.S95775.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelmeier C, Vestbo J. COPD assessment: I, II, III, IV and/or A, B, C, D. Eur Respir J. 2014;43(4):949-50. doi:10.1183/09031936.00019714.</mixed-citation><mixed-citation xml:lang="en">Vogelmeier C, Vestbo J. COPD assessment: I, II, III, IV and/or A, B, C, D. Eur Respir J. 2014;43(4):949-50. doi:10.1183/09031936.00019714.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев В. С., Мухин Н. А., Мухин А.В и др. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая нефрология. 2014;2: 4-29.</mixed-citation><mixed-citation xml:lang="en">Moiseev VS, Muhin NA, Muhin AV, et al. National recommendations. Cardiovascular risk and chronic kidney disease: strategies for cardio-nephroprotection. Clinical nephrology. 2014;2:4-29. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Eisen A, Hoshen M, Balicer RD, et al. Estimated Glomerular Filtration Rate Within the Normal or Mildly Impaired Range and Incident Cardiovascular Disease. Am J Med. 2015 Sep;128(9):1015-22.e2. doi:10.1016/j.amjmed.2015.03.024.</mixed-citation><mixed-citation xml:lang="en">Eisen A, Hoshen M, Balicer RD, et al. Estimated Glomerular Filtration Rate Within the Normal or Mildly Impaired Range and Incident Cardiovascular Disease. Am J Med. 2015 Sep;128(9):1015-22.e2. doi:10.1016/j.amjmed.2015.03.024.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Болотова Е. В., Дудникова А. В., Являнская В. В. Особенности диагностики хронической болезни почек у больных хронической обструктивной болезнью легких. Клиническая нефрология. 2017;1:18-22.</mixed-citation><mixed-citation xml:lang="en">Bolotova EV Dudnikova AV Iavlianskaia VV. Features of diagnosis of chronic kidney disease in patients with chronic obstructive pulmonary disease. Clinical nephrology. 2017;1:18-22. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis. 2014;7:13-24. doi:10.2147/IJNRD.S40522.</mixed-citation><mixed-citation xml:lang="en">Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis. 2014;7:13-24. doi:10.2147/IJNRD.S40522.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fruchter O, Yigla M, Kramer MR. Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease.Am J Med Sci. 2015;349(4):338-43. doi:10.1097/MAJ.0000000000000435.</mixed-citation><mixed-citation xml:lang="en">Fruchter O, Yigla M, Kramer MR. Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease.Am J Med Sci. 2015;349(4):338-43. doi:10.1097/MAJ.0000000000000435.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the Vitamin D-binding gene. Thorax. 2010;65:215-20. doi:10.1136/thx.2009.120659.</mixed-citation><mixed-citation xml:lang="en">Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the Vitamin D-binding gene. Thorax. 2010;65:215-20. doi:10.1136/thx.2009.120659.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lee HM, Liu M, Lee K, et al. Does low vitamin D amplify the association of COPD with total and cardiovascular disease mortality? Clin Cardiol. 2014;37(8):473-8. doi:10.1002/clc.22284.</mixed-citation><mixed-citation xml:lang="en">Lee HM, Liu M, Lee K, et al. Does low vitamin D amplify the association of COPD with total and cardiovascular disease mortality? Clin Cardiol. 2014;37(8):473-8. doi:10.1002/clc.22284.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Durup D, Jorgensen HL, Christensen J, et al. Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. Clin Endocrinol Metab. 2015;100(6):2339-46. doi:10.1210/jc.2014-4551.</mixed-citation><mixed-citation xml:lang="en">Durup D, Jorgensen HL, Christensen J, et al. Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. Clin Endocrinol Metab. 2015;100(6):2339-46. doi:10.1210/jc.2014-4551.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
